AbbVie, Calico raise their age-related disease alliance funding to $3.5bnAbbVie and Alphabet spin-out Calico Life Sciences have agreed to fund their seven-year-old partnership seeking treatments for diseases Share XAbbVie, Calico raise their age-related disease alliance funding to $3.5bnhttps://pharmaphorum.com/news/abbvie-calico-raise-their-age-related-disease-alliance-funding-to-3-5bn/
Regeneron, AZ team up on drugs for obesity “superpower” geneAstraZeneca has formed a partnership with Regeneron to investigate the potential of treating obesity using drugs directed at Share XRegeneron, AZ team up on drugs for obesity “superpower” genehttps://pharmaphorum.com/news/regeneron-az-team-up-on-drugs-for-obesity-superpower-gene/
BioNTech’s mRNA vaccine drive now includes malaria, TB shotsFlushed with the success of its COVID-19 vaccine, BioNTech has pressed the accelerator on the development of shots Share XBioNTech’s mRNA vaccine drive now includes malaria, TB shotshttps://pharmaphorum.com/news/biontechs-mrna-vaccine-drive-now-includes-malaria-tb-shots/
First published data backs CanSino’s inhaled COVID vaccineEarly-stage clinical data with CanSino Biologics’ inhaled COVID-19 vaccine show that it was able to stimulate neutralising antibodies Share XFirst published data backs CanSino’s inhaled COVID vaccinehttps://pharmaphorum.com/news/first-published-data-backs-cansinos-inhaled-covid-vaccine/
Boehringer takes alteplase to phase 3 for COVID, but drops antibodyBoehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its Share XBoehringer takes alteplase to phase 3 for COVID, but drops antibodyhttps://pharmaphorum.com/news/boehringer-takes-alteplase-to-phase-3-for-covid-but-drops-antibody/
Allergan builds case for first drug therapy for presbyopiaIf you are in middle aged and find you have to hold your phone at arm’s length to Share XAllergan builds case for first drug therapy for presbyopiahttps://pharmaphorum.com/news/allergen-builds-case-for-first-drug-therapy-for-presbyopia/
Syneos Health appoints Michael Brooks as Chief Development OfficerSyneos Health has appointed Michael Brooks as its new chief development officer. In this newly created role, Brooks Share XSyneos Health appoints Michael Brooks as Chief Development Officerhttps://pharmaphorum.com/news/syneos-health-appoints-michael-brooks-as-chief-development-officer/
Ogilvy Health promotes Rebecca Carter to Head of Social MediaOgilvy Health UK has promoted Rebecca Carter to the newly created role of Head of Social Media. Carter Share XOgilvy Health promotes Rebecca Carter to Head of Social Mediahttps://pharmaphorum.com/sales-marketing/ogilvy-health-promotes-rebecca-carter-to-head-of-social-media/
Look out BMS, Cytokinetics has its eye on mavacamten’s turfShares in Cytokinetics surged after it reported positive mid-stage results for CK-274, a drug for hypertrophic cardiomyopathy (HCM) Share XLook out BMS, Cytokinetics has its eye on mavacamten’s turfhttps://pharmaphorum.com/news/look-out-bms-cytokinetics-has-its-eye-on-mavacamtens-turf/
